Boehringer Ingelheim has entered into a collaboration and global license agreement for Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 to be developed for fibrosing interstitial lung diseases including IPF
With this new partnership Boehringer Ingelheim further expands its commitment to bring new treatments to patients with fibrosing interstitial lung diseases including IPF
Bridge Biotherapeutics stands to receive up to more than EUR 1.1 billion assuming all milestones are met
INGELHEIM, Germany & SEONGNAM, Korea -- (BUSINESS WIRE) --
Boehringer Ingelheim and Bridge Biotherapeutics Inc. today announced that they are entering into a new collaboration and license agreement with the goal of developing Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 for patients with fibrosing interstitial lung diseases, including IPF. BBT-877 is currently in Phase I clinical studies and is anticipated to enter Phase II testing within the next 12 months.
Both companies will initially focus on developing the compound for the treatment of IPF, an area of high-unmet medical need and one of the key focus areas of Boehringer Ingelheim. Boehringer Ingelheim has developed OFEV® (nintedanib), an antifibrotic drug shown to slow disease progression by reducing lung function decline and currently approved for the treatment of IPF in more than 70 countries around the world including the US, the EU and Japan.
IPF is a rare, debilitating and fatal lung disease affecting approximately three million people worldwide. It causes progressive scarring of the lungs, resulting in continual and irreversible deterioration in lung function and breathing difficulties. BBT-877 inhibits autotaxin, an enzyme mediating a key pro-fibrotic event in multiple cell types. It has shown a promising safety and efficacy profile in pre-clinical models for fibrosing interstitial lung diseases and potential for combination with the current standard of care.
Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit said, “We look forward to working with the team at Bridge Biotherapeutics to develop a new treatment option for patients with IPF. This new collaboration complements our growing pipeline in fibrosing interstitial lung diseases and is a sign of our determination to bring the next generation of treatment options to these patients.”
“Bridge Biotherapeutics is pleased to partner with Boehringer Ingelheim, a recognized leader in IPF. The expertise of Boehringer Ingelheim will ensure that our novel therapeutic candidate can be developed to potentially address unmet medical needs of IPF patients worldwide,” said James Lee, CEO of Bridge Biotherapeutics.
“This is a transformational event for Bridge Biotherapeutics with a total potential value in excess of EUR 1.1 billion. It is a testament to the company’s excellence in the development of novel therapeutics for disease areas with high unmet medical need,” commented B. Chris Kim, PhD, a board member of Bridge Biotherapeutics based in Cambridge, Massachusetts.
Bridge Biotherapeutics will receive upfront and near term payments of EUR 45 million and is eligible to receive up to more than EUR 1.1billion in potential payments based upon the successful achievement of specified development, regulatory, and commercial milestones and staggered, up to double digit royalties.
联想研究发现企业可采取三个步骤来实现超越界
彰显出MSCI在提高环境、社会与治理(ESG)透明度
非营利性融资平台Heroe5推出The
Advanced Energy宣布推出超宽温度范围的高精度
Biban 2023开幕当天签署超过25项协议
新的CloudBlue Connect提供能统一多渠道
孙建锋——德艺双馨艺术家献礼建党99周年
Lightbits扩大私有、混合和边缘部署的横向扩展分
上饶人的“尔滨”冰雪世界
爱科与博世、巴斯夫xarvio数字农业解决方案及
穆迪分析借助AI支持功能增强CreditEdge
Sintavia聘请Brian Haggenmiller
Synergis Adept在G2的2022年春季报告中
Eagle Eye Networks和Brivo
渤海中学北校区高一第一次家长学校交流大会隆
Kyriba’s Currency Impact
OCF成员认证首批通用云接口(UCI)平台
Personalis宣布与MapKure合作
蒙碟儿铜锅涮 一个有历史的火锅落户中卫市
ROSEN鼓励损失超过10万美元的Citrix
阳信县第二高级中学2019年十大工作亮点
艾贝特亮相2020中国国际光电博览会,共鉴光电
2019年5个灸手可热的文化旅游热点
国际土著语言大会定于6月在不列颠哥伦比亚省